Cargando…
TUDCA-treated chronic kidney disease-derived hMSCs improve therapeutic efficacy in ischemic disease via PrP(C)
Although autologous human mesenchymal stem cells (hMSCs) are a promising source for regenerative stem cell therapy in chronic kidney disease (CKD), the barriers associated with pathophysiological conditions limit therapeutic applicability to patients. We confirmed that level of cellular prion protei...
Autores principales: | Yoon, Yeo Min, Kim, SangMin, Han, Yong-Seok, Yun, Chul Won, Lee, Jun Hee, Noh, Hyunjin, Lee, Sang Hun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383184/ https://www.ncbi.nlm.nih.gov/pubmed/30785084 http://dx.doi.org/10.1016/j.redox.2019.101144 |
Ejemplares similares
-
TUDCA-Treated Mesenchymal Stem Cells Protect against ER Stress in the Hippocampus of a Murine Chronic Kidney Disease Model
por: Lee, Jun Hee, et al.
Publicado: (2019) -
Proliferation and Osteogenic Differentiation of hMSCs on Biomineralized Collagen
por: de Melo Pereira, Daniel, et al.
Publicado: (2020) -
PrP(C) Aptamer Conjugated–Gold Nanoparticles for Targeted Delivery of Doxorubicin to Colorectal Cancer Cells
por: Go, Gyeongyun, et al.
Publicado: (2021) -
(18)F- based Quantification of the Osteogenic Potential of hMSCs
por: Grossner, Tobias, et al.
Publicado: (2020) -
IRX5 promotes adipogenesis of hMSCs by repressing glycolysis
por: Jiang, Bulin, et al.
Publicado: (2022)